HALIFAX, April 9 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and
solutions, today announced the appointment of Mr. André Archimbaud to the
Company's Board of Directors.
"We are pleased to have Mr. Archimbaud join the Board of Directors of
MedMira. As we aggressively move our business strategy forward, Mr.
Archimbaud's in-depth industry knowledge and experience in developing
strategic partnerships will be invaluable to our Company," said Dr. James
Smith, Chairman of the Board, MedMira Inc.
Mr. Archimbaud is an executive with extensive experience in the life
sciences sector, serving in various roles in the industry for more than 25
years. Most recently he served as Senior Vice President, Life Sciences for the
Société Générale de Financement (SGF) du Québec, a government-owned investment
entity contributing to the development of life sciences both locally and
internationally. Prior to SGF, Mr. Archimbaud was the President and Chief
Executive Officer of Vancouver-based Kinetek Pharmaceuticals Inc., a biotech
start-up recognized for its expertise in the field of molecular biology
applied to oncology. Mr. Archimbaud also held progressively senior roles in
sales, marketing, business development and licensing in his 20 years with
Ipsen Beaufour, a European pharmaceutical company.
Mr. Archimbaud takes the place of Mr. David Harris, who resigned from
MedMira's Board of Directors after serving a two year term as a Director.
"The Board thanks Mr. Harris for his contribution to MedMira during his
tenure as a Board member," said Dr. Smith.
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold under the
Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global
markets. MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the European
Union. MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For more information visit MedMira's website at
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For further information:
For further information: Andrea Young, Corporate Communications,
MedMira, (902) 450-1588, email@example.com